

Early Detection


Early Cure

NPC GOLD™ is a non-invasive screening and monitoring blood test for nasopharyngeal cancer (NPC) that is developed and validated in Singapore¹. NPC screening is made easy for earlier treatment and higher survival rates^{1,2,3}.

Sensitive

Targets the highly stable CpG islands of *Bam*HI-W repetitive sequences in the EBV genome for higher test sensitivity^{1,4}, improving detection for Stage I and II NPC.

Superior detection rate for *Bam*HI-W CpG DNA qPCR^{1,4}



Data from National Cancer Centre Singapore

Specific

Targets the NPC specific 143bp EBV fragments^{1,4}, reducing false positives⁵. Blood collection in Streck Tube reduces B-cell lysis that affects plasma circulating EBV.

How NPC GOLD™ helps

Positive result

It is recommended to repeat NPC GOLD™ test 4 weeks later to determine persistent positivity³. If the result is again positive, the patient should undergo further evaluation for NPC.

Negative result

Annual screening is recommended for early detection based on published cohort follow-up data³.

Technology

Real-time quantitative polymerase chain reaction (qPCR)

Target

*Bam*HI-W CpG islands in Epstein-Barr Virus (EBV)

Sample Requirement

Blood in 1 Streck Tube (9mL)

Turnaround time

3-5 working days

Sensitivity

89%

Specificity

100%

Limit of Detection

50 IU/ mL

[1] Vo, J. H. et al. Scientific Reports. 2016;6(1):1-9
 [2] Howlader, N. et al. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute.
 [3] Chan, K. A. et al. N Engl J Med. 2017;377(6):513-522
 [4] Tan, M.H. & Vo, J. H. 2016. PCT/SG2016/050611
 [5] Lam, W.J. et al. PNAS. 2018;115(22):E5115-E5124